Economic issues related to the health sector are addressed by CVBF through pharmacoeconomics techniques (cost-minimization analysis, cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis) and HTA Assessment 
All clinical research

Haemoglobinophaties

A pharmacoeconomic and HTA evaluation on the use of deferiprone formulation in paediatrics aimed to guide the inclusion of the drug in the current Protocol and Guidelines.

Health technology assessment report on iron chelators used in paediatric patients affected by congenital haemoglobinopathies. The objective of this study is to collect, discuss and compare evidence on iron chelators, investigating all the relevant domains: health problem and current use of technology, description and technical characteristics of drugs and therapies, safety, clinical effectiveness, costs and economic evaluations. Clinical data from Deep Trials will be used to populate an economic model, consistently adapted according to the new clinical and economic evidence.  

Chronic neuropathic pain

A HTA report including a cost/benefit evaluation aimed to guide the implementation of clinical recommendations for the use of gabapentin as monotherapy and/or add-on therapy.

Sedation in children

A market analysis aimed to determine the share of paediatric patients that could be treated with clonidine for sedation including possible competitors and potential profitability.

Pharmacoeconomic and HTA evaluation on deferiprone

A pharmacoeconomic and HTA evaluation on the use of deferiprone formulation in paediatrics aimed to guide the inclusion of the drug in the current Protocol and Guidelines.

Market analysis for clonidine

A market analysis aimed to determine the share of paediatric patients that could be treated with clonidine for sedation including possible competitors and potential profitability.

HTA report for gabapentin

A HTA report including a cost/benefit evaluation aimed to guide the implementation of clinical recommendations for the use of gabapentin as monotherapy and/or add-on therapy.

DEEP HTA report

Health technology assessment report on iron chelators used in paediatric patients affected by congenital haemoglobinopathies. The objective of this study is to collect, discuss and compare evidence on iron chelators, investigating all the relevant domains: health problem and current use of technology, description and technical characteristics of drugs and therapies, safety, clinical effectiveness, costs and economic evaluations. Clinical data from Deep Trials will be used to populate an economic model, consistently adapted according to the new clinical and economic evidence.  

All clinical research